This article needs to be updated. The reason given is: Subject is now the executive director of the University of Maryland Greenebaum Comprehensive Cancer Center.(February 2025) |
This article may rely excessively on sources too closely associated with the subject , potentially preventing the article from being verifiable and neutral.(June 2020) |
Taofeek Kunle Owonikoko | |
|---|---|
| Born | |
| Alma mater | |
| Scientific career | |
| Institutions | Emory University Johns Hopkins University |
| Thesis | Genetische Heterogenität in Adenokarzinomen des Ösophagus (2000) |
Taofeek Kunle Owonikoko is an American physician who is Professor and Vice-Chair for Faculty Development, Department of Haematology and Medical Oncology at the Winship Cancer Institute. His research considers small cell lung cancer. He was a 2019 Emory University Woodruff Leadership Academy Fellow.
Owonikoko is from Nigeria. He attended the Obafemi Awolowo University, where he specialised in medicine.[ citation needed ] Owonikoko completed his residency at the Lagos University Teaching Hospital. In 1998 he was awarded a German research fellowship to join Heinrich Heine University Düsseldorf.[ citation needed ] Whilst in Germany Owonikoko earned a doctoral degree in anatomical pathology. [1]
In 2001 Owonikoko joined Johns Hopkins University as a postdoctoral fellow, where he worked in molecular imaging. [2] Owonikoko was designated as a Distinguished Cancer Scholar in the Georgia Cancer Coalition in 2008. That year he joined Emory University as an associate professor. [3]
He specialises in small cell lung cancer.[ citation needed ] He leads clinical trials into novel immunotherapy drugs, which can be used to treat aggressive and recurrent cancers. [4] He has studied the efficacy of talazoparib as a treatment for small cell lung cancer patients with homologous recombination repair deficiency. [5]
Owonikoko has called for more people of color to be involved with clinical cancer trials. [6] In particular, Black patients are below 4% of patients involved in clinical trials for lung cancer. [6] He believes that this underrepresentation perpetuates healthcare outcome inequality. [6]